After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)

WSW, NY, August 25th, 2026, FinanceWire

Moderna's cancer news sent its stock up 177% in a single day (NASDAQ: MRNA), from $62.96 to $174.38. Roughly $44 billion of market value was added in one session, while Merck rose 12.6% to a record high. The reason was simple: a large Phase 3 study showed that Moderna's personalized cancer vaccine worked better with Merck's Keytruda (NYSE: MRK) than Keytruda alone at keeping high-risk melanoma from coming back or spreading.

That was a huge result for Moderna, but it also sent a simple message across biotech: helping a blockbuster cancer drug work better can be enormously valuable. Keytruda generated $31.7 billion in sales in 2025 and is one of the biggest cancer drugs in the world. Moderna did not replace it. It added something new and made the overall treatment more effective. That is where Silexion Therapeutics (NASDAQ: SLXN) starts to get interesting. Silexion is developing SIL204 for pancreatic cancer, and recent lab results suggest the drug may do more than attack the cancer directly. It may also make cancer cells easier for the immune system to find and kill.

Why Pancreatic Cancer Is So Hard

Keytruda works by helping the body's immune system recognize and attack cancer. It has changed treatment in several major cancers, but pancreatic cancer remains one of the toughest. These tumors are often very good at hiding from the immune system, which is one reason drugs like Keytruda have had limited success for most pancreatic cancer patients.

Silexion is trying to attack that problem at its source. SIL204 is designed to switch off KRAS, a faulty gene found in roughly 90% of pancreatic cancers. KRAS acts like a stuck accelerator that tells cancer cells to keep growing. By shutting down the message that produces the faulty KRAS protein, Silexion hopes to slow or stop that growth across several common KRAS mutations.

Silexion's New Immune Angle

The newer part of the story is what SIL204 may do to the tumor itself. In recent lab studies, Silexion saw changes in several immune signals tied to how cancer cells are recognized, attacked and able to hide from the immune system. Put simply, the treated cancer cells appeared easier for the immune system to see and more vulnerable to being killed.

That matters because pancreatic cancer is especially difficult for immune-based drugs. If SIL204 can both attack KRAS and make the cancer easier for the immune system to recognize, it could open another path for the program beyond its current use with chemotherapy. Silexion has already said the findings support eventually studying SIL204 together with drugs like Keytruda, though that combination has not been tested in patients and the supporting data so far are preclinical.

Why the Moderna Read-Through Matters

Moderna and Silexion use different technologies, but the bigger opportunity is easy to understand. Moderna just showed how valuable it can be when a new cancer treatment makes Keytruda work better. Outside research has also shown that shutting down KRAS can help immune cells attack pancreatic tumors more effectively, which gives Silexion a reason to explore the same combination idea from a different direction.

That gives SIL204 two paths for investors to watch. The first is the one Silexion is already pursuing: attacking KRAS-driven pancreatic cancer. The second would be a future immunotherapy combination, where SIL204 could help turn a tumor that hides from the immune system into one that drugs like Keytruda can attack more effectively. That could broaden the opportunity around the same drug without changing the core KRAS story.

The Clinical Program Is Already Moving

Silexion is also moving beyond the lab. On July 29, the company activated Tel Aviv Sourasky Medical Center, known as Ichilov, as the first site in its Phase 2/3 study of SIL204 in locally advanced pancreatic cancer. Patient screening is cleared to begin, and additional centers in Israel and Germany are moving toward activation. The study starts with about 18 patients for safety before expanding into a randomized group of about 166 patients.

The current trial is testing SIL204 with standard chemotherapy, not Keytruda, so the immunotherapy angle is a future opportunity rather than part of the study now underway. But the basic setup is clear: Silexion already has a Phase 2/3 pancreatic cancer program moving into patients, while new lab data are opening a second possible use for the same drug. Moderna's $44 billion one-day move showed how quickly the market can react when a new cancer approach helps an established treatment work better. Silexion now has to show what SIL204 can do in patients.

Recent news from Silexion Therapeutics (NASDAQ: SLXN):

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

Silexion Therapeutics Receives Approval from Germany’s BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Silexion Therapeutics Corp (the "Issuer") for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially. This article discusses a clinical-stage biotechnology company; investing in such companies carries substantial risk, including the risk that ongoing or planned clinical trials may not succeed or lead to regulatory approval. Readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.

Contact